Induction of Foxp3 and activation of Tregs by HSP gp96 for treatment of autoimmune diseases.
iScience 2021;
24:103445. [PMID:
34877502 PMCID:
PMC8633978 DOI:
10.1016/j.isci.2021.103445]
[Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 09/16/2021] [Accepted: 11/10/2021] [Indexed: 01/06/2023] Open
Abstract
Upregulation and stabilization of Foxp3 expression in Tregs are essential for regulating Treg function and immune homeostasis. In this study, gp96 immunization showed obvious therapeutic effects in a Lyn–/– mouse model of systemic lupus erythematosus. Moreover, gp96 alleviated the initiation and progression of MOG-induced experimental autoimmune encephalomyelitis. Immunization of gp96 increased Treg frequency, expansion, and suppressive function. Gene expression profiling identified the NF-κB family member p65 and c-Rel as the key transcription factors for enhanced Foxp3 expression in Treg by gp96. Mutant gp96 within its Toll-like receptor (TLR) binding domain, TLR2 knockout mice, and mice with cell-specific deletion of MyD88, were used to demonstrate that gp96 activated Tregs and induced Foxp3 expression via a TLR2-MyD88-mediated NF-κB signaling pathway. Taken together, these results show that gp96 immunization restricted antibody-induced and Th-induced autoimmune diseases by integrating Treg expansion and activation, indicating its potential clinical usefulness against autoimmune diseases.
SLE symptoms in Lyn–/– mice are ameliorated by gp96 immunization
Tregs expanded by gp96 provide potential in suppressing Th-mediated EAE
Gp96 promotes Treg proliferation, stability, and suppressive function
Gp96 binds to and activates Treg in a TLR2-MyD88-NF-кB-Foxp3 pathway
Collapse